Palliative Treatment of Locally Advanced Non Metastatic Lung Cancer

作     者：Gael Kietga Wilfried Mosse Patricia Agbanglanon Bertrand Compaore Davy Nchepo Evrard Seka Sanae Elmajjaoui Hanane Elkacemi Tayeb Kebdani Amine Lachgar Noureddine Benjaafar Gael Kietga;Wilfried Mosse;Patricia Agbanglanon;Bertrand Compaore;Davy Nchepo;Evrard Seka;Sanae Elmajjaoui;Hanane Elkacemi;Tayeb Kebdani;Amine Lachgar;Noureddine Benjaafar

作者机构：Radiotherapy Department National Institute of Oncology Rabat Morocco 

出 版 物：《Journal of Cancer Therapy》 (癌症治疗（英文）)

年 卷 期：2021年第12卷第2期

页      面：71-77页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Lung Cancer Palliative Treatment Locally Advanced 

摘      要：Introduction: To determine the proportion and the reasons which lead to palliative treatment in patients initially a candidate for concomitant chemoradiotherapy (CCRT).Methods: A retrospective study including patients followed for locally advanced lung cancer newly diagnosed from April 1, 2016, to 12/31/2017 in the radiotherapy department of the National Oncology Institute who received palliative treatment.Results: We collected 52 patients out of a total of 225 stage III patients (23%) followed by lung cancer candidates for CCRT who had undergone palliative treatment. The mean age in our series was 61.23 years [22-81] with 86% male. The majority of patients (71%) had Performance Status (PS) ≤ 2. Histological confirmation was obtained by pathological examination in all our patients. It was an adenocarcinoma (ADK) in 54% of cases;squamous cell carcinoma in 46% of cases. The reasons for palliative treatment were mainly due to dosimetric constraints: large tumor volume 22/52 (42%);the tumor location close to the bone marrow in 15 of 52 (29%) patients;and general Performance Status impairment (29%) in 15 of 52 patients. Palliative treatment consisted of palliative chemotherapy in 37 of 52 patients (71%), span style=font-family:Verd